Avenue Therapeutics Inc (NASDAQ:ATXI)’s share price hit a new 52-week high on Monday . The company traded as high as $6.00 and last traded at $5.39, with a volume of 3800 shares. The stock had previously closed at $5.52.

A number of equities analysts have weighed in on the stock. Oppenheimer set a $8.00 target price on shares of Avenue Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, August 15th. ValuEngine raised shares of Avenue Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $11.00 target price on shares of Avenue Therapeutics in a research note on Wednesday, August 15th.

The company has a market capitalization of $58.86 million, a price-to-earnings ratio of -3.16 and a beta of -2.35.

WARNING: This news story was published by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2018/11/19/avenue-therapeutics-atxi-hits-new-52-week-high-at-6-00.html.

Avenue Therapeutics Company Profile (NASDAQ:ATXI)

Avenue Therapeutics, Inc, a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain.

Featured Story: What Is An Exchange-Traded Fund (ETF)?

Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.